Calypte Biomedical Corp (fka CBMC)

[OttomanRosendahl]

Calypte Biomedical To Add Biotech Jobs

November 19, 2010 By Chris Taylor Leave a Comment

Portland, Oregon-based Calypte Biomedical Corporation has been awarded a tax credit of $244,479 under U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) programme.

The company develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection and other sexually transmitted and chronic diseases. Calypte’s product line includes both point-of-care rapid tests and an EIA based incidence test.

Calypte intends to bring to the US market a rapid test for HIV-1/2 using oral fluid instead of blood.

The company believes that rapid oral fluid testing offers dramatic potential for improvement in HIV medicine. Field trials of Calypte’s second generation oral fluid rapid test are underway, in preparation for a US FDA clinical trial in 2011.

Calypte says it is the only company to have earned FDA approval for a urine-based HIV-1 antibody-screening test and supplemental Western blot.

The company also plans to add new biotech jobs.

The funding from the grant award will allow Calypte to help fight the spread of HIV. The company will also be using the funding to hire new personnel and perform clinical trials.

insert-text-here